null
Phosphorothioate: Enhancing Stability in Oligonucleotide-Based Therapies

Phosphorothioate: Enhancing Stability in Oligonucleotide-Based Therapies

Phosphorothioate is a chemical modification commonly used in oligonucleotide-based therapies to enhance the stability and efficacy of therapeutic nucleic acids. In this modification, one of the non-bridging oxygen atoms in the phosphate backbone of a nucleotide is replaced by a sulfur atom. This seemingly small change provides a significant benefit: phosphorothioate oligonucleotides are far more resistant to enzymatic degradation, which is critical for maintaining their activity in the body. The modification is widely used in antisense oligonucleotides (ASOs), RNA interference (RNAi), and aptamer therapies to improve cellular uptake, bioavailability, and stability .


1. Structure and Chemistry of Phosphorothioates

In a standard phosphodiester bond within nucleic acids, two oxygen atoms connect each nucleotide to form the backbone. The phosphorothioate modification involves replacing one of these non-bridging oxygen atoms with sulfur, creating a phosphorothioate linkage.


Key Structural Benefits of Phosphorothioate Modification


  • Resistance to Nucleases: Phosphorothioate linkages are less susceptible to degradation by nucleases, increasing the oligonucleotide's half-life in biological environments .
  • Increased Binding Affinity: The sulfur atom enhances binding with target mRNA and cellular proteins, facilitating effective inhibition or modulation of gene expression .
  • Increased Hydrophobicity: The sulfur substitution increases oligonucleotide hydrophobicity, aiding cellular uptake and membrane interaction, which is beneficial for therapeutic delivery .

2. Mechanisms of Action for Phosphorothioate Oligonucleotides

Phosphorothioate modifications are crucial in several gene-targeting and regulatory mechanisms:


Antisense Oligonucleotides (ASOs)


In antisense technology, phosphorothioate-modified oligonucleotides bind to specific mRNA sequences, promoting RNAse H-mediated degradation of the target mRNA. This results in the reduction of target gene expression, commonly used for diseases associated with the overexpression of certain genes .


RNA Interference (RNAi) and siRNA


For siRNA or miRNA therapeutics, phosphorothioate modifications improve oligonucleotide stability and help protect the RNA strands from premature degradation. The modification can also enhance the delivery of siRNAs to target tissues, although it may sometimes reduce RNAi activity if extensively applied .


Aptamers and Molecular Inhibitors


Phosphorothioate modifications are used in aptamers, which are short, single-stranded oligonucleotides designed to bind to target molecules. By increasing stability, phosphorothioate modification extends aptamer efficacy in therapeutic and diagnostic applications .


3. Applications of Phosphorothioate Modifications in Therapeutics

Phosphorothioate-modified oligonucleotides are applied across various therapeutic areas due to their enhanced stability and specificity:


Antisense Therapy for Genetic Disorders


Antisense oligonucleotides with phosphorothioate modifications have been effective in Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD) treatments, where they are used to correct splicing defects and reduce pathogenic protein production .


Oncology


Phosphorothioate modifications are essential in cancer therapies, where antisense oligonucleotides are used to silence oncogenes or inhibit pathways crucial to cancer cell survival. These modified oligonucleotides demonstrate improved bioavailability and prolonged activity, enhancing therapeutic effects in tumor environments .


Cardiovascular Diseases


Therapeutics targeting lipid metabolism disorders, such as antisense oligonucleotides targeting ApoB or PCSK9, use phosphorothioate-modified structures to decrease LDL cholesterol levels, showing promise in managing hyperlipidemia and cardiovascular diseases 


4. Advantages and Challenges of Phosphorothioate Modification

Advantages 


Advantage
Description
Enhanced Stability
Increased resistance to nuclease degradation, leading to prolonged therapeutic action.
Improved Cellular Uptake
Hydrophobicity and protein binding enhance uptake and retention within cells.
Versatility in Applications
Effective in a range of gene modulation therapies, from gene silencing to splicing correction.

Challenges


Despite the benefits, phosphorothioate modifications have some limitations:


  • Increased Toxicity: The sulfur substitution can lead to off-target effects and toxicity, especially if used at high doses .
  • Reduced Specificity: Phosphorothioate modifications increase non-specific binding to serum
    proteins and other cellular components, which may reduce target specificity.
  • Cost of Synthesis: The chemical modification adds complexity to oligonucleotide synthesis, increasing production costs .

5. Future Directions in Phosphorothioate Research

Research into phosphorothioate modifications focuses on refining oligonucleotide structures to maximize therapeutic efficacy while minimizing off-target effects and toxicity. Current studies are examining combinations of phosphorothioate with other modifications like 2’-O-methyl or locked nucleic acids (LNAs) to achieve an optimal balance of stability, specificity, and safety .


Emerging Applications


  • RNA Splicing Modulation: Phosphorothioate oligonucleotides show potential in treating diseases caused by splicing errors by redirecting splicing patterns.
  • CRISPR/Cas9 Delivery: Modified oligonucleotides with phosphorothioate backbones are being
    explored as delivery vehicles for CRISPR components, ensuring stability and enhancing cellular uptake .

Conclusion

Phosphorothioate modification has become a cornerstone in developing stable and effective oligonucleotide therapeutics, offering significant advantages in antisense therapy, RNAi, and aptamer technology. With ongoing advancements and refinements, phosphorothioate-modified oligonucleotides hold the promise to tackle a broad spectrum of genetic, oncological, and cardiovascular disorders.


References

  1. Crooke, S.T., 2017. Molecular mechanisms of antisense oligonucleotides. Nucleic Acid Therapeutics, 27(2), pp.70-77.
  2. Stein, C.A., 2016. Efficacy and safety of antisense oligonucleotides in gene silencing. Molecular Therapy, 24(2), pp.197-204.
  3. Eckstein, F., 2014. Phosphorothioate oligonucleotides: stability and cellular delivery. Biochemical Society Transactions, 42(3), pp.1087-1091.
  4. Evers, M.M., et al., 2015. Emerging oligonucleotide therapies for genetic neuromuscular disorders. Nature Reviews Drug Discovery, 14(4), pp.246-264.
  5. Bennett, C.F., Swayze, E.E., 2010. RNA targeting and its therapeutic applications. Annual Review of Pharmacology and Toxicology, 50, pp.259-293.
  6. Corey, D.R., 2017. Chemical modification: the key to clinical applications of RNA interference. The Journal of Clinical Investigation, 127(9), pp.3219-3221.
  7. Khvorova, A., Watts, J.K., 2017. The chemical evolution of oligonucleotide therapies of clinical utility. Nature Biotechnology, 35(3), pp.238-248.
  8. Tuerk, C., Gold, L., 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249(4968), pp.505-510.
  9. Finkel, R.S., et al., 2017. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. New England Journal of Medicine, 377(18), pp.1723-1732.
  10. Tabernero, J., et al., 2013. Antisense oligonucleotides: the next frontier in cancer treatment? Nature Reviews Clinical Oncology, 10(10), pp.563-576.
  11. Gaudet, D., et al., 2015. Efficacy of antisense oligonucleotide therapy targeting ApoB in patients with familial hypercholesterolemia. The Lancet, 385(9969), pp.331-340.
  12. Gagnon, K.T., et al., 2014. Clinical pharmacokinetics and bioavailability of antisense therapeutics. Molecular Therapy, 22(2), pp.337-347.

15th Nov 2024 Zainab Riaz

Recent Posts